AU2016360763B2 - Stable cell lines for retroviral production - Google Patents

Stable cell lines for retroviral production Download PDF

Info

Publication number
AU2016360763B2
AU2016360763B2 AU2016360763A AU2016360763A AU2016360763B2 AU 2016360763 B2 AU2016360763 B2 AU 2016360763B2 AU 2016360763 A AU2016360763 A AU 2016360763A AU 2016360763 A AU2016360763 A AU 2016360763A AU 2016360763 B2 AU2016360763 B2 AU 2016360763B2
Authority
AU
Australia
Prior art keywords
nucleic acid
retroviral
vector
acid sequences
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016360763A
Other languages
English (en)
Other versions
AU2016360763A1 (en
Inventor
Sabine Johnson
Celeste PALLANT
Eirini Vamva
Conrad VINK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1520761.6A external-priority patent/GB201520761D0/en
Priority claimed from GBGB1609303.1A external-priority patent/GB201609303D0/en
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of AU2016360763A1 publication Critical patent/AU2016360763A1/en
Application granted granted Critical
Publication of AU2016360763B2 publication Critical patent/AU2016360763B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C12N15/8673—Special methods for packaging systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C12N7/025—Packaging cell lines, e.g. transcomplementing cell lines, for production of virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/00051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
    • C12N2830/006—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB tet repressible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/40—Vector systems having a special element relevant for transcription being an insulator
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Seal Device For Vehicle (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2016360763A 2015-11-24 2016-11-21 Stable cell lines for retroviral production Ceased AU2016360763B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1520761.6 2015-11-24
GBGB1520761.6A GB201520761D0 (en) 2015-11-24 2015-11-24 Stable cell lines for retroviral production
GB1609303.1 2016-05-26
GBGB1609303.1A GB201609303D0 (en) 2016-05-26 2016-05-26 Stable cell lines for retroviral production
PCT/EP2016/078336 WO2017089308A1 (en) 2015-11-24 2016-11-21 Stable cell lines for retroviral production

Publications (2)

Publication Number Publication Date
AU2016360763A1 AU2016360763A1 (en) 2018-05-31
AU2016360763B2 true AU2016360763B2 (en) 2020-11-05

Family

ID=57354376

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016360763A Ceased AU2016360763B2 (en) 2015-11-24 2016-11-21 Stable cell lines for retroviral production

Country Status (17)

Country Link
US (3) US20170145388A1 (enExample)
EP (2) EP3489353B8 (enExample)
JP (1) JP7098521B2 (enExample)
KR (1) KR102091957B1 (enExample)
CN (1) CN108291208A (enExample)
AU (1) AU2016360763B2 (enExample)
BR (1) BR112018010635A2 (enExample)
CA (1) CA3006288A1 (enExample)
DE (1) DE102016122316A1 (enExample)
ES (2) ES2939617T3 (enExample)
FR (1) FR3044016A1 (enExample)
GB (1) GB2544892B (enExample)
IL (2) IL259254A (enExample)
IT (1) IT201600117326A1 (enExample)
RU (1) RU2752498C2 (enExample)
SA (1) SA518391623B1 (enExample)
WO (1) WO2017089308A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7816612B2 (en) * 2005-12-21 2010-10-19 Ishida Co., Ltd. Rotary measuring device
FR3044017B1 (fr) 2015-11-24 2019-05-03 Glaxosmithkline Intellectual Property Development Limited Procede de transfection transitoire pour la production retrovirale
GB201706121D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Stable cell lines for retroviral production
GB201715052D0 (en) 2017-09-19 2017-11-01 Oxford Genetics Ltd Vectors
ES2951857T3 (es) 2017-12-22 2023-10-25 Oxford Biomedica Ltd Vector retroviral
CA3123449A1 (en) * 2018-12-21 2020-06-25 Lonza Walkersville, Inc. Automated production of viral vectors
US12037599B2 (en) 2019-08-23 2024-07-16 Lonza Walkersville, Inc. Methods and constructs for production of lentiviral vector
CN114829588A (zh) * 2019-12-18 2022-07-29 隆萨沃克斯维尔股份有限公司 用于慢病毒载体的瞬时产生的方法和构建体
GB202004371D0 (en) 2020-03-26 2020-05-13 Glaxosmithkline Ip Dev Ltd CAR constructs
GB202005096D0 (en) 2020-04-07 2020-05-20 Glaxosmithkline Modified vectors for production of retrovirus
CN113528515B (zh) * 2020-04-22 2023-05-05 中国科学院分子植物科学卓越创新中心 基于CRISPR-Cas13a干预阻断病毒逆转录转座的技术
CA3183599A1 (en) * 2020-05-15 2021-11-18 Ivexsol, Inc. Compositions and methods for producing stable viral vector producer cells for cell and gene therapy
CN112430582B (zh) * 2020-12-04 2022-05-03 北京艺妙神州医药科技有限公司 一种慢病毒稳定包装细胞系及其制备方法
CN117377691A (zh) 2021-03-19 2024-01-09 葛兰素史密斯克莱知识产权发展有限公司 靶向密蛋白3的嵌合抗原受体和治疗癌症的方法
WO2022225973A1 (en) * 2021-04-20 2022-10-27 The Regents Of The University Of California Packaging cells with targeted gene knockouts that improve retroviral vector titers
CN120187857A (zh) * 2023-01-10 2025-06-20 南京传奇生物科技有限公司 调控序列及其用途
WO2024218341A1 (en) 2023-04-19 2024-10-24 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for car-t and car-nk cells
WO2024218345A1 (en) 2023-04-21 2024-10-24 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for antibody-drug conjugates and bispecific antibodies

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003400A1 (en) * 1993-07-23 1995-02-02 Johns Hopkins University School Of Medicine Recombinationally targeted cloning in yeast artificial chromosomes
WO2002072836A2 (en) * 2001-03-09 2002-09-19 Bundesrepublik Deutschland Replication-competent molecular clones of porcine endogenous retrovirus class a and class b derived from pig and human cells
US6677155B1 (en) * 1999-04-22 2004-01-13 The General Hospital Corporation Triple hybrid amplicon vector systems to generate retroviral packaging lines
WO2008099148A1 (en) * 2007-02-12 2008-08-21 Ark Therapeutics Ltd. Production of lentiviral vectors

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
ATE309000T1 (de) * 1995-06-27 2005-11-15 Bavarian Nordic As Verkapselte zellen die virenpartikeln produzieren
FR2751223B1 (fr) * 1996-07-19 1998-12-04 Rhone Merieux Formule de vaccin polynucleotidique felin
EP1179083A4 (en) * 1999-04-22 2003-04-23 Gen Hospital Corp TRIPLE HYBRID AMPLICON VECTOR SYSTEMS FOR THE PRODUCTION OF RETROVIRUS PACKING CELL LINES
CA2371946A1 (en) 1999-04-29 2000-11-09 Aarhus University Expression of heterologous genes from an ires translational cassette in retroviral vectors
WO2001091802A1 (en) * 2000-05-30 2001-12-06 Baylor College Of Medicine Chimeric viral vectors for gene therapy
US6689601B2 (en) 2000-09-01 2004-02-10 E. I. Du Pont De Nemours And Company High growth methanotropic bacterial strain
US6586251B2 (en) * 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
IL157746A0 (en) 2001-05-30 2004-03-28 Chromos Molecular Systems Inc Chromosome-based platforms
US6835568B2 (en) * 2001-10-30 2004-12-28 Virxsys Corporation Regulated nucleic acid expression system
JP4598398B2 (ja) * 2002-02-01 2010-12-15 オックスフォード バイオメディカ （ユーケー） リミテッド ウイルスベクター
DE60314541T2 (de) * 2002-11-25 2008-02-28 Bavarian Nordic A/S Mindestens zwei ati promotoren enthaltendes rekombinantes pockenvirus
EP1743028A2 (en) * 2004-04-28 2007-01-17 The Trustees Of The University Of Pennsylvania Polyvalent viral vectors and a system for production thereof
EP1652932A1 (en) * 2004-11-02 2006-05-03 GBF Gesellschaft für Biotechnologische Forschung mbH Method for the generation of virus producing cell lines and cell lines
PT2088193E (pt) * 2004-11-24 2011-02-24 Anaeropharma Science Inc Novo vector vaivém
JPWO2010131747A1 (ja) * 2009-05-15 2012-11-08 国立大学法人 東京大学 ウイルス産生細胞
SI2480678T1 (sl) * 2010-09-02 2014-06-30 Molmed Spa Stabilno proizvajanje lentivirusnih vektorjev
US9273324B2 (en) * 2010-12-05 2016-03-01 Andrew S. Belmont Recombinant gene expression
WO2012170431A2 (en) * 2011-06-06 2012-12-13 Bluebird Bio, Inc. Improved geneswitch systems
FR2979919B1 (fr) * 2011-09-12 2015-12-11 Centre Nat Rech Scient Genomes lentiviraux chimeriques non-integratifs comme vaccins innovants contre vih-1
GB201202516D0 (en) * 2012-02-13 2012-03-28 Ucl Business Plc Materials and methods relating to packaging cell lines
JP2015529466A (ja) * 2012-09-14 2015-10-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 鎌状赤血球症の幹細胞遺伝子治療のためのレンチウイルスベクター
EP2909324B1 (en) * 2012-10-25 2020-02-26 Tocagen Inc. Retroviral vector with mini-promoter cassette
US11078464B2 (en) * 2013-08-30 2021-08-03 Amgen Inc. High titer recombinant AAV vector production in adherent and suspension cells
GB2538324A (en) * 2015-05-15 2016-11-16 Glaxosmithkline Ip Dev Ltd Packaging cell line for retroviral production
GB2538321A (en) * 2015-05-15 2016-11-16 Glaxosmithkline Ip Dev Ltd Artificial chromosome for retroviral production
EP3139086B1 (en) * 2015-09-01 2018-05-23 Philips Lighting Holding B.V. Lighting device with a wireless communication antenna
FR3044017B1 (fr) * 2015-11-24 2019-05-03 Glaxosmithkline Intellectual Property Development Limited Procede de transfection transitoire pour la production retrovirale

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003400A1 (en) * 1993-07-23 1995-02-02 Johns Hopkins University School Of Medicine Recombinationally targeted cloning in yeast artificial chromosomes
US6677155B1 (en) * 1999-04-22 2004-01-13 The General Hospital Corporation Triple hybrid amplicon vector systems to generate retroviral packaging lines
WO2002072836A2 (en) * 2001-03-09 2002-09-19 Bundesrepublik Deutschland Replication-competent molecular clones of porcine endogenous retrovirus class a and class b derived from pig and human cells
WO2008099148A1 (en) * 2007-02-12 2008-08-21 Ark Therapeutics Ltd. Production of lentiviral vectors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Félix Recillas-Targa, Molecular Biotechnology, vol. 34, no. 3, (2006-11), pages 337 - 357, URL: http://rd.springer.com/content/pdf/10.1385/MB:34:3:337.pdf, (2017-01-23) *
M. NIEBERT ET AL, JOURNAL OF VIROLOGY., US, (2002-03-15), vol. 76, no. 6, doi:10.1128/JVI.76.6.2714-2720.2002, ISSN 0022-538X, pages 2714 - 2720 *
YAJIN NI ET AL, JOURNAL OF GENE MEDICINE, JOHN WILEY & SONS, INC, US, vol. 7, no. 6, doi:10.1002/JGM.726, ISSN 1099-498X, (2005-06), pages 818 - 834, (2005-02-03) *

Also Published As

Publication number Publication date
IL259254A (en) 2018-07-31
JP7098521B2 (ja) 2022-07-11
JP2018534937A (ja) 2018-11-29
EP3489353C0 (en) 2023-07-26
KR102091957B1 (ko) 2020-03-20
BR112018010635A2 (pt) 2018-11-27
ES2939617T3 (es) 2023-04-25
DE102016122316A1 (de) 2017-05-24
RU2018122636A (ru) 2019-12-25
AU2016360763A1 (en) 2018-05-31
EP3380604B1 (en) 2022-12-28
EP3380604A1 (en) 2018-10-03
KR20180079351A (ko) 2018-07-10
IL282603B (en) 2022-05-01
GB2544892B (en) 2017-11-15
EP3489353A1 (en) 2019-05-29
US20200123505A1 (en) 2020-04-23
US20180320147A1 (en) 2018-11-08
CA3006288A1 (en) 2017-06-01
RU2752498C2 (ru) 2021-07-28
GB2544892A (en) 2017-05-31
FR3044016A1 (fr) 2017-05-26
CN108291208A (zh) 2018-07-17
EP3489353B1 (en) 2023-07-26
IL282603A (en) 2021-06-30
EP3489353B8 (en) 2023-08-30
WO2017089308A1 (en) 2017-06-01
RU2018122636A3 (enExample) 2020-04-02
ES2959326T3 (es) 2024-02-23
US20170145388A1 (en) 2017-05-25
GB201619643D0 (en) 2017-01-04
SA518391623B1 (ar) 2022-10-30
IT201600117326A1 (it) 2018-05-21

Similar Documents

Publication Publication Date Title
AU2016360763B2 (en) Stable cell lines for retroviral production
AU2016359838B2 (en) Transient transfection method for retroviral production
US11795474B2 (en) Stable cell lines for retroviral production
GB2538321A (en) Artificial chromosome for retroviral production
GB2538324A (en) Packaging cell line for retroviral production
GB2544891A (en) Transient transfection method for retroviral production

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired